02 Aug, 2021 09:15 AM
Dr Sandhya Buchanan joins SUDA to lead the technology transfer, manufacturing, and quality efforts for its newly acquired invariant Natural Killer T (iNKT) cell therapy platform.
Dr Buchanan has ...read more
26 Jul, 2021 10:13 AM
SUDA Pharmaceuticals Ltd (ASX: SUD), a biotechnology company focused on developing therapies to treat cancer and conditions that affect the central nervous system, today released its Appendix 4C for...read more
01 Jul, 2021 05:29 PM
Sequoia Financial Group Limited (ASX: SEQ or the Company) is pleased to announce the launch of Sequoia Family Office.
Continuing the successful expansion of our Wealth Management business, we are...read more
22 Jun, 2021 10:10 AM
SUDA Pharmaceuticals Ltd (ASX: SUD) is pleased to announce that the Company has received firm commitments for a capital raising by placing up to 96,163,997 ordinary shares to institutional and sophi...read more
18 Jun, 2021 10:22 AM
SUDA Pharmaceuticals Ltd (ASX: SUD), today announces that it has signed a global, exclusive Licence Agreement with Imperial College London for a novel invariant Natural Killer T (iNKT) cell therapy ...read more
18 Jun, 2021 09:26 AM
The securities of Suda Pharmaceuticals Ltd (‘SUD’) will be placed in trading halt at the request of SUD, pending it releasing an announcement. Unless ASX decides otherwise, the securitie...read more